Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype characterized by the absence of estrogen receptor, progesterone receptor, and HER2 expression, leading to poor clinical outcomes and resistance to targeted therapies. This evidence concerns the gene PGR and triple-negative breast carcinoma.